Jun. 2 at 4:39 PM
$SLS $GLSI
it took 4.5 Months from the 72nd to 80th Event
or 1 event every 3 weeks.
Its now been a full 3 weeks since the 78th Event May 11.
-- Likely Now at 79.
-- Be Holding as many as you can when the 80th Event is Announced. That PR is going to Move SLS up to
$20 /
$3.8B in Market Value, and Climbing - as the Market Begins to digest GPS true value.
- A Revolutionary Immunotherapy that will treat 40,000 AML Remission patients each year - with an adinfinite dosing compounding Revenue.
-
$28B Total Addressable Market.
And Gps will set records for patient uptake rates, Safe, easy to administer, 2X - 4X Survival Advantage.
Ps
$ABBV $RHHBY $BMY Own VEN Aza - VEN - Aza Failed the VIALE-M CR1 Remission Maintenance Phase 3 Trial.
they Know Ven Aza Failed the Control Arm Patients in the SLS CR2 Remission Maintenance Trial - and that it is GPS doing what its done in all prior trials, Prevent Relapse and Extend Survival, including in 2 Phase 2 Trials for CR maintenance.
